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Abstract: Despite its name, prostate-specific membrane antigen (PSMA) has been shown using
immunohistochemistry (IHC) to also be over-expressed in the tumor neovasculature of a wide
variety of solid tumors other than prostate carcinoma. Accordingly, positron-emitting radiolabeled
small molecules targeting PSMA, initially developed for positron emission tomography in prostate
carcinomas, are currently being explored for their staging and restaging potential as an alternative
imaging modality in other solid tumor types where 18-F-fluorodeoxyglucose (FDG)-PET imaging
has low diagnostic accuracy. In this paper, the currently available literature in this field is reviewed.
Preliminary, mainly retrospective studies are encouraging, with evidence of improved diagnostic
sensitivity and specificity in clear cell renal carcinoma, glioma, and hepatocellular carcinoma,
leading to a change in patient management in several patients. However, the results published thus
far warrant confirmation by larger prospective studies additionally assessing the longitudinal impact
on patient outcomes.
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1. Introduction
Prostate-specific membrane antigen (PSMA), an integral membrane glycoprotein ectopeptidase
with both folate hydrolase and N-acylated, a-linked dipeptidase activities, was first characterized in
1986 by the murine monoclonal antibody 7E11, derived from mice immunized with partially purified
cell membrane fractions isolated from the human prostate adenocarcinoma cell line LNCap [1–3].
Subsequent immunohistochemical (IHC) analysis showed PSMA to be highly expressed in the epithelial
cells of the prostate with an intense over-expression in prostate cancer, where its increased expression
was shown to correlate with advanced disease stage and the presence of distant metastases [2,4,5].
In recent years, PSMA-targeting positron emission tomography (PET) imaging, primarily using the
radiolabeled urea-based small molecular PSMA inhibitors 68Ga-PSMA-HBED-CC and 18F-DCFPyL,
has emerged as an important modality for imaging prostate carcinomas with promising clinical results,
leading to an increase in the number of studies exploring the role of PSMA PET in detection, staging,
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restaging at biochemical recurrence, prognostication, and treatment response assessment of prostate
carcinoma [5]. In addition, limited available data suggest that alpha- and beta-emitting PSMA-targeting
derivatives are highly promising for the treatment of prostate cancer, and rapid development of these
agents is anticipated in the years ahead assuming adequate isotope availability and appropriate clinical
trials [5].
Aside from its overexpression on epithelial cells of prostate carcinomas, immunohistochemistry
studies have shown that PSMA is also upregulated on the endothelial cells of the neovasculature
of a wide variety of other solid tumors. Accordingly, in patients suffering from these tumor types,
PET imaging using PSMA-targeting radiolabeled tracers may prove of interest for the staging, restaging,
and identification of patients that might potentially benefit from PSMA-targeting treatment strategies.
In this paper, the currently available literature in this field is reviewed. Only studies describing results
in at least three patients are included.
2. Renal Cell Carcinoma
Renal cell carcinoma (RCC) is a collection of different types of tumors with distinct genetic
characteristics, histological features, and, to some extent, clinical phenotypes [6]. The most common
types of renal cell carcinoma are the proximal-convoluted-tubule-derived clear cell renal carcinoma
(CRCC), accounting for up to 75% of renal cell carcinomas; the papillary renal cell carcinoma (PRCC),
accounting for another 15% of renal cell carcinomas; and the collecting-tubule-derived chromophobe
renal cell carcinoma (ChRCC), accounting for 5% of renal cell carcinomas and oncocytomas. As diagnosis
of RCC is frequently not made until disease is either locally advanced and unresectable or metastatic,
and as many patients who initially present with resectable disease eventually recur, the overall survival
of patients suffering from RCC is poor; the estimated five-year survival rate is only 50% [6–8]. While CT
and MRI imaging are routinely used for staging RCC, particularly in small lesions and subcentimeter
lymph nodes potentially representing early metastases, definitive diagnosis remains difficult using
these imaging modalities [9]. Furthermore, the role of bone scintigraphy and 18-F-fluorodeoxyglucose
(FDG) PET/CT imaging in the staging of RCC is limited. As a consequence, a subgroup of patients
with limited metastatic burden, termed oligo-metastatic disease, may be deprived of long-term disease
control or cure. In the search for novel, clinical, useful molecular-targeted imaging biomarkers that may
improve staging and grading and thus also hopefully improve outcome in RCC patients, a number of
authors have reported on 68Ga-PSMA-PET CT imaging results in RCC patients.
68GA-PSMA-HBED-CC PET imaging: Rhee et al. prospectively performed 68Ga-PSMA-HBED-CC
PET/CT imaging within 4 weeks following standard imaging (CT of the chest and abdomen and,
in some cases, additionally ultrasound, bone scan, or MRI) in ten patients with newly diagnosed renal
tumor (eight CRCC, one PRCC, one unclassified) and suspicion of metastatic disease on standard
imaging according to RECIST 1.1 criteria (measurable lesions defined as lymph nodes greater than
or equal to 10 mm in the short axis, or tumor lesions with minimum size of 10 mm by CT scan or
20 mm by chest X-ray) [10]. Of the 86 PET abnormalities reported as primary or metastatic disease,
histological correlation was available in 36, out of which 35 proved to harbor renal cell carcinoma
deposits. Inversely, out of 32 CT-identified lesions that were surgically removed or biopsied for
histopathological correlation, only 24 were consistent with RCC. The greatest advantage of 68Ga-PSMA
PET/CT imaging over standard CT proved to be its ability to identify small lesions (the smallest
node identified was 6 mm) or lesions in areas where visualization is difficult, such as in the liver,
especially when contrast cannot be used. 68Ga-PSMA HBED-CC PET imaging led to the alteration of
patient management in two patients: in one patient, 68Ga-PSMA-HBED-CC PET imaging identified
a small liver metastasis that was not revealed on non-contrast MRI, US, or CT, whereas in another
patient, 68Ga-PSMA-HBED-CC PET imaging identified a tumor thrombus extension into a lumbar
vein which was excised using the PET image as a guide. Of interest, the SUVmax of the PRCC proved 6
times lower than the average SUVmax of the remaining tumors. Sawicki et al. retrospectively reviewed
68Ga-PSMA-HBED-CC PET imaging results obtained in six RCC patients (four CRCC, one PCRCC,
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and one chromophobe RCC) [11]. 68Ga-PSMA-HEBD-CC PET/CT imaging identified 22 lesions:
5 primary RCCs, 16 metastases (all of which were found in two CRCC patients), and 1 benign lesion
which was consistent with ectopic salivary gland tissue in the left masseter muscle. Eight of the 16
metastases displayed focal 68Ga-PSMA-HBED-CC uptake: 2 pleural metastases, 3 bone metastases,
and 3 lung metastases (size range 1.0–1.7 cm). The remaining eight PET-negative metastases were all
lung metastases identified on CT with size ranging from 0.5 to 0.9 cm. Furthermore, visualization
of the primary RCC was not feasible as none of the primary tumors showed 68GaPSMA-HBED-CC
uptake above that of the surrounding renal parenchyma. The authors concluded that 68Ga-PSMA
HEBD-CC PET/CT does not offer additional value in the local staging of RCC when compared to CT
imaging. Inversely, in a recent retrospective study by Raveenthiran et al., patient management as
defined based on diagnostic CT findings was changed in 8 out of 16 RCC patients (8 CRCC, 1 PRCC,
1 oncocytoma, 6 unknown histology) following subsequent 68Ga-PSMA HEBD-CC PET/CT imaging;
68Ga-PSMA-HBED-CC PET imaging identified new metastatic disease in two patients not present on
standard CT imaging, refuted disease in involved lymh nodes as defined by diagnostic CT imaging
in three patients (stable on restaging), and identified new synchronous primaries (two prostate and
one lung carcinoma) in three patients [12]. Likewise, in 22 RCC patients (20 CRCC patients, 1 CRCC
patient, and 1 transitional cell carcinoma), patient management as defined based on initial diagnostic
CT findings was changed in 13 out of 20 patients following subsequent 68Ga-PSMA HEBD-CC PET/CT
imaging performed at restaging: in 4/9 patients, new sites of metastatic disease were identified;
in 5/9 patients, 68Ga-PSMA-HBED-CC PET/CT imaging refuted disease; and in another 4 patients,
a synchronous primary prostate carcinoma was identified. Finally, Siva et al. reported on the diagnostic
value of 68GaPSMA-HBED-CC PET imaging compared to conventional imaging as well as FDG
PET/CT imaging in a retrospective series of eight RCC patients (seven CRCC and one PRCC) [13].
In all but two cases—the sole PRCC and one CRCC—FDG PET and 68Ga-PSMA-HEBD-CC PET
findings proved concordant in the detection of the site of disease. In one of the latter two patients,
two additional lesions were detected on 68GA-PSMA-HBED-CC PET imaging, resulting in a change in
treatment planning (from stereotactic ablative radiotherapy to systemic therapy). Of interest, both PET
techniques demonstrated response to therapy earlier than CT or MRI imaging.
18F-DCFPyL PET/CT imaging: In a series of five patients by Rowe et al., 18 lesions suspicious for
CRCC were found on conventional imaging versus 28 on 18F-DCFPyL PET, 17 of which corresponded
to sites of disease on conventional imaging [14]. The only lesion that PET was unable to identify
was a 6 mm liver lesion. In contrast, PET identified small lymph nodes in the mediastinum or
retroperitoneum as well as occult bone metastases that were not identified on conventional imaging.
Meyer et al. prospectively performed 18F-DCFPyL PET/CT imaging in 14 patients diagnosed with
oligo-metastatic CRCC based on standard-of-care conventional cross-sectional imaging with CT and/or
MRI. In 4 out of 14 patients, 18F-DCFPyL PET/CT imaging identified a total of 12 additional lesions,
resulting in 3 patients being considered as no longer suffering from oligo-metastatic but from more
widespread disease [15]. Additionally, in one patient who still met the criteria for oligo-metastatic
disease, new sites of disease were identified. Finally, Yin et al. performed 18F-DCFPyL PET/CT imaging
in eight patients suffering from metastatic non-clear cell RCC (three PRCC, two chromophobe RCC,
two unclassified RCCs, and one Xp11 translocation RCC) [16]. Of the 73 putative sites of metastatic
disease and 3 primary renal lesions identified on the basis of conventional imaging, no lesions were
identified on PET/CT imaging without a corresponding finding on conventional imaging, and only
10 of the 73 suspected lesions had definitive uptake of 18F-DCFPyL PET/CT imaging. An additional
14 lesions showed equivocal uptake, and the remaining 49 lesions showed no significant tracer uptake
above the background activity.
3. Transitional Cell Carcinoma of the Bladder
Bladder tumors, 90% of which are derived from the urothelium, are characterized by a high
recurrence rate and an aggressive clinical course [17–19]. Parameters predicting bladder carcinoma
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progression and survival include the depth of tumor infiltration, the histologic differentiation grade,
and the presence of concomitant carcinoma in situ. While 80% of transitional cell carcinomas of the
bladder are initially superficial, 30%–90% of these will develop a local recurrence following localized
therapy, of which 15%–20% will evolve to invasive and/or metastatic stages following retreatment
(local, systemic, intra-vesical) [20]. Accordingly, any biological marker capable of selecting those
patients that are at risk of progression and who may thus benefit from earlier aggressive treatment is of
clinical interest. Campbell et al. performed 18F-DCFPyL PET/CT imaging in three patients suffering
from metastasized urothelial carcinoma [21]. While 18F-DCFPyL PET/CT imaging allowed for the
detection of sites of urothelial carcinoma in all three patients (respectively a recurrent prostatic urethra
lesion, a bladder mass and pelvic lymph nodes, and retroperitoneal lymph nodes and lung metastases),
overall levels of radiotracer uptake were low. Consistent with this observation, IHC staining of tissue
from one of the imaged patients demonstrated a low level of neovascularization and nearly absent
PSMA expression.
4. Primary Brain Tumors
The most common primary brain tumors are gliomas, with grades I, II, and III usually progressing
to a poor outcome over 2 to 10 years and the most aggressive grade IV (glioblastoma multiforme (GBM))
usually resulting in death within 2–3 years following diagnosis [22–24]. The current standard therapy of
gliomas includes maximal safe surgical resection, followed by concurrent radiation (with temozolomide
(TMZ), an oral alkylating chemotherapy agent in glioblastoma), and then adjuvant chemotherapy with
TMZ in glioblastoma [22]. Extensive and complete surgical resection of gliomas is difficult because
these tumors are frequently invasive, in the case of glioblastoma, and are often in eloquent areas of the
brain, including areas that control speech, motor function, and the senses. Because of the high degree
of invasiveness and the issue of location, radical resection of the primary tumor mass is often not
curative, and infiltrating tumor cells invariably remain within the surrounding brain, later on leading
to disease progression or recurrence [23,24]. At recurrence, a minority of patients are eligible for second
surgery or reirradiation, based on appropriate patient selection. In temozolomide-pretreated patients,
progression-free survival rates at 6 months of 20%–30% may be achieved with either nitrosoureas,
temozolomide in various dosing regimens, or bevacizumab. Therapeutic targeting of the endothelium
in gliomas is attractive as it may be exposed to a therapeutic agent much more readily than the tumor
substance which is protected by the blood–brain barrier. As such, PSMA targeting in gliomas may
offer a theranostic outlook for glioma patients.
Sasikumar et al. performed 68Ga-PSMA-HBED-CC PET/CT imaging in 10 patients with suspected
recurrence on MRI of a previously treated glioblastoma [25]. The 68Ga-PSMA-HBED-CC PET scan
was positive in nine patients, and subsequent histopathology proved it to be true recurrence. In the
scan-negative case on MRI follow-up at nine months, no evidence of disease could be identified.
The same authors compared results obtained using FDG PET and 68Ga-PSMA-HBED-CC PET imaging
in five treated cases of glioblastoma with suspected recurrence; the findings from 68Ga-PSMA-HBED-CC
PET/CT proved concordant with those from the FDG PET/CT scan [26]. However, when compared
to FDG PET/CT, 68Ga-PSMA-HBED-CC PET/CT showed better visualization of the recurrent lesion
(presence/absence) owing to its significantly high tumor-to-background ratio (TBR, mean TBR of
12.9 versus 0.96). Similar results were reported by Verma et al. and Salas Fragomeni et al. [27,28]. In a
series of 10 glioma patients (7 GBM and 3 low-grade gliomas), Verma et al. found high FDG uptake in
GBM, whereas the low-grade gliomas were not detected in the FDG study because of the fact that their
activity was comparable to that of the physiological brain uptake [27]. Inversely, all of the gliomas
were readily identified on the 68Ga-PSMA-HBED-CC PET/CT examinations, with the glioblastoma
multiforme lesions presenting systematically with a higher SUVmax value (range 9.64–24.55) when
compared to the low-grade gliomas (3.65–3.25). Salas Fragomeni et al. performed 18F-DCFPyL PET
imaging in a series of three prospectively recruited patients suffering from high-grade glioma [28].
All three gliomas, probable GBM as defined by MRI imaging, demonstrated increased radiotracer uptake
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when compared with the background, similar to the results obtained using 68Ga-PSMA-HEBD-CC
PET imaging. The SUVmax values, however, proved lower than those reported using 68Ga-PSMA
PET imaging. The lower uptake when compared to that in 68Ga-PSMA-HBED-CC imaging may relate
to differences in the biology of the gliomas studied or may be ascribed to the imaging agent.
5. Thyroid Carcinoma
Surgical thyroid removal is the definitive procedure for the management of differentiated thyroid
carcinoma (DTC, papillary and follicular thyroid carcinoma) [29,30]. Approximately 4–6 weeks after
surgical thyroid removal, patients may have radioactive iodine (RAI) therapy to detect and destroy
any metastasis and residual tissue in the thyroid. If thyroid cancer recurs and the recurrence is
radioiodine avid, the latter may be treated with radioiodine [29]. On the other hand, if patients
present with RAI-refractory disease, which tends to be significantly worse than radioiodine-avid
or non-progressive disease, they may be included in phase I, II, and III studies that are currently
being conducted to evaluate the efficacy of new molecular-targeted drugs such as the tyrosine kinase
inhibitors and re-differentiation drugs. The overall response rate of these drugs/therapies ranges
between 0% and 53%, depending on whether the patients had been previously treated with these drugs,
the performance status, and the extent of disease [30]. With the introduction of 68Ga-PMSA-HBED-CC
PET imaging in patients suffering from prostate carcinoma, incidental uptake of 68Ga-PSMA-HBED-CC
found in thyroid lesions has led a limited number of authors to explore in more detail the uptake of
PSMA-targeting PET ligands by thyroid carcinoma neovasculature.
Lütje et al. studied six patients with RAI-refractory, FDG-positive metastasized DTC [31]. In five
out of six patients, 68Ga-PSMA-HBED-CC PET imaging identified 41 lesions, all of which were
confirmed by FDG PET/CT or conventional CT imaging. Whereas 68Ga-PSMA-HBED-CC PET imaging
was fully concordant with FDG PET imaging in three patients, in the remaining two patients, only the
most prominent lesions detected on FDG PET imaging were visualized using 68Ga-PSMA-HBED-CC
PET imaging (SUVmax values ranged from 3.3 to 39.7). Finally, Verma et al. studied 10 patients suffering
from metastasized DTC, 2 of which proved negative on iodine scintigraphy [32]. 68Ga-PSMA-HBED-CC
PET imaging identified 30/32 lesions identified by all possible imaging techniques, whereas FDG PET
imaging identified 23 lesions. Of the 30 lesions identified, 21 were localized to the bone. Furthermore,
PSMA PET localized a lesion in each of the two RAI-refractory patients, similar to FDG PET imaging.
6. Breast Carcinoma
Breast carcinoma is the second leading cause of cancer-related death among women [33,34].
While novel therapies have improved the overall survival rate in breast carcinoma patients,
treatment-related side effects and resistance warrant the need for new risk stratification and therapeutic
targets. In this regard, PSMA expression on newly formed vessels in breast carcinoma may prove an
interesting target for imaging and treatment.
Sathekge et al. studied 19 patients suffering from breast carcinoma in whom 81 tumor lesions
were identified; out of these, 6 primary or recurrent lesions, 2 lymph nodes, and 5 metastases
proved negative on 68Ga-PSMA-HBED-CC PET imaging, yielding an overall detection rate of 84%
for 68-PSMA-HBED-CC PET/CT imaging [35]. The SUVmean values of distant metastases proved
significantly higher when compared to those of primary or local recurrences or involved lymph nodes.
Of interest, the 68Ga-PSMA-HEBD-CC SUVmean values of progesterone-receptor-positive lesions
proved to be not significantly different from those obtained in progesterone-receptor-negative lesions.
7. Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC) accounts for approximately 20%–35% of all salivary gland
malignancies, arising more often in the minor salivary glands. It is characterized by slow local
progression, extensive perineural spread, and a tendency for delayed onset of distant metastases [36].
Following surgery, frequently followed by adjuvant radiation therapy, almost half of the patients develop
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slowly growing distant metastases within the first five years following diagnosis, significantly reducing
patient prognosis; the reported five-year survival rates are 7%–32%. While the current guidelines
consider FDG PET/CT imaging at initial presentation to assess disseminated disease, FDG uptake
in ACC is lower than that in squamous cell carcinoma, and not all ACC show detectable uptake.
Klein Nulent et al. performed 68Ga-PSMA-HBED-CC PET/CT imaging in nine ACC patients because
of either suspected local recurrence or distant metastasis [37]. In addition, the authors performed
IHC for PSMA on representative tumor samples, all of which proved positive. Furthermore, with the
exception of one patient, all matched cases showed concordant positive PSMA expression between
primary and recurrent cases. All nine 68Ga-PSMA-HBED-CC PET examinations clearly depicted tracer
uptake in areas of the former primary tumor or localizations of distant metastasis. Three examinations
showed tracer uptake in four new lesions suspected of being metastases; progression of formerly
diagnosed metastases was seen in four patients.
8. Hepatocellular Carcinoma
The diagnosis of hepatocellular carcinoma (HCC), the most frequent primary liver malignancy,
is challenged by the silent course of the disease, fluctuating serum alpha-fetoprotein levels,
and inconclusive radiological findings [38]. Whereas FDG PET imaging has been shown to be
of clinical value for detecting metastatic lymph nodes, distant metastases, and recurrent HCC, it is of
limited value for the initial diagnosis of HCC. Accordingly, novel tracers with a higher sensitivity than
that of FDG for primary HCC identification are of interest. In this regard, Kessler et al. assessed the
potential role of 68Ga-PSMA-HBED-CC PET in a pilot study of seven patients (six newly diagnosed)
suffering from HCC with 41 liver lesions, of which 37 were suspected to be tumoral, the remaining
4 being regenerative nodules [39]. Thirty-six of the 37 tumor lesions and none of the regenerative
nodules showed tracer uptake, while only ten lesions were FDG avid. The one lesion that was negative
on 68Ga-PSMA-HBED-CC PET also proved nonenhancing on contrast CT, whilst the remaining lesions
were, and 68Ga-PSMA-HBED-CC uptake proved highly correlated with vascularity. Of interest,
68Ga-PSMA-HBED-CC PET/CT imaging identified unexpected extra-hepatic metastases in two out of
the seven patients studied. More recently, Kuyumcu et al. reported on results obtained in 17 HCC
patients who were referred for restaging of a known HCC and who underwent both FDG and
68Ga-PSMA-HBED-CC PET/CT imaging [40]. Whereas in two patients HCC uptake was both FDG
and 68Ga-PSMA-HBED-CC PET negative, FDG uptake proved higher than that of the PSMA-targeting
ligand (both visually and quantitatively (SUVmax)) in four patients (one of these patients being FDG
negative), whereas in nine patients Ga-PSMA-HEBD-CC uptake by their HCC proved higher when
compared to that of FDG (respectively negative in two patients).
9. Discussion
To date, large, well-designed studies addressing the role of 68GA-PSMA-HBED-CC or 18F-DCFPyl
PET/CT imaging targeting PSMA expression on tumors other than prostate carcinoma are lacking.
Nevertheless, the limited available data, mainly retrospective in nature, are promising and in line with
available histological studies on PSMA expression in the various tumor types studied. Not surprisingly,
the majority of the tumor types under study are those in which FDG, the most common tumor
imaging agent for PET/CT imaging, has low sensitivity either due to high physiological uptake in the
surrounding normal tissue, e.g., brain tumors; due to their indolent course reflected in a low glucose
metabolism, e.g., adenoid cystic carcinoma; or to specific underlying molecular characteristics limiting
their degree of FDG accumulation, e.g., overactivity of the glucose-6-phosphatase enzyme (removing
18F from the FDG molecule) in differentiated HCC.
Consistent with published data in pathology showing present yet intermediate expression of PSMA
in the tumor neovasculature of non-clear cell RCC subtypes, only a small portion of sites of non-clear cell
RCC were shown to take up the PSMA-targeting radiotracer 18F-DCFPyL, indicating that PSMA-based
PET/CT imaging is likely not appropriate for imaging of these tumors. Inversely, in CRCC demonstrating
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high levels of PSMA expression, 68Ga-PSMA-HBED-CC and 18F-DCFPyl PET/CT imaging may have
a clinically useful role in the evaluation of those patients presenting with indeterminate findings on
conventional imaging, such as retroperitoneal and mediastinal lymph nodes measuring less than
1 cm in diameter [10]. Furthermore, the higher reported detection rate of metastatic lesions when
using PSMA-targeting PET/CT imaging in CRCC as compared to conventional imaging suggests that
PSMA-targeting PET/CT imaging may play a significant role in confirming the diagnosis as well as
assessing the extent of oligometastatic CRCC, thereby significantly impacting the outcome for these
patients [10]. As indicated by a recent systematic review, complete metastasectomy in oligometastatic
CRCC patients is associated with a significant gain in median overall survival (36.5–142 months versus
8.4–27 months in those patients who undergo an incomplete metastasectomy) [41]. In urothelial
carcinoma, the relatively scant expression of PSMA as evidenced from PSMA IHC studies is likely to
limit the utility of PSMA-targeted PET imaging. In patients suffering from glioma, limited available
data suggest that it may prove highly accurate for the purpose of detecting tumor recurrence, with the
absence of PSMA-targeting PET ligand uptake in the normal brain parenchyma and rupture of
the blood–brain barrier allowing facile accessibility of the ligand to its target resulting in high
tumor-to-background ratios and straightforward visualization of the recurrence. A similar potential
role for recurrence detection using PSMA PET imaging may also apply to adenoid cystic carcinoma
of the head and neck. In patients suffering from thyroid carcinoma, limited available data suggest
that PSMA PET imaging may prove of specific interest in the subsets of RAI-refractory and aggressive
high-grade thyroid carcinoma as it tends to detect more metastatic RAI-resistant foci and proved more
effective in recognizing brain lesions when compared to FDG PET/CT. In breast carcinoma, PSMA PET
imaging demonstrated a considerable variation of PSMA expression in primary and metastatic breast
carcinoma lesions from one patient to another as well as from one lesion to another within one patient,
supporting the fact that it is a heterogeneous disease. Finally, limited available data suggest a potential
role for PSMA-targeted PET imaging in the differential diagnosis and staging of HCC.
The high uptake of PSMA-targeting ligands by solid tumors other than prostate carcinomas,
based on underlying overexpression of this marker on their neovasculature and the lack thereof on
normal vessels as evidenced by histology, renders PSMA a highly interesting target for antiangiogenic
therapy. First, PSMA-targeting agents such as, e.g., 177Lu-PSMA-targeting or PSMA-targeting
nanoparticles containing chemotherapeutics may either selectively destroy tumor neovascularization
or allow for a selective delivery of high doses of chemotherapeutics, overcoming tumor resistance whilst
sparing normal tissues. Patients that could potentially benefit from this type of treatment, e.g., those with
glioblastoma, could be selected based on their PSMA PET imaging results. Second, according the Jain
hypothesis, treatment with anti-angiogenic agents such as bevicuzamb, which captures free human
vascular endothelial growth factor-A (VEGF-A, are assumed to improve chemotherapy efficacy by
transiently normalizing the leaky character of the tumor vessels, leading to more effective oxygen
and drug delivery [42]. Our group previously showed in an animal model that when given outside
this normalization window, chemotherapeutics proved ineffective [43]. Thus, suboptimal clinical
results obtained using bevacizumab in combination with chemotherapy may have resulted from an
inappropriate sequence in the timing of the administration of chemotherapeutics. As preclinical
findings suggest that PSMA may be involved in the leaky character of the endothelium of newly
formed vessels [44], PSMA-targeting PET/CT imaging may provide a potential tool for characterization
of the “normalization window” which, in turn, may then allow for optimization of the efficacy of
VEGF-targeting therapies such as bevacizumab.
10. Conclusions
PSMA expression in the tumor neovasculature has been established using IHC in a wide variety
of tumors. Positron-emitting small molecules targeting PSMA have been developed for PET imaging,
and their potential as an alternative imaging modality for staging and restaging in tumor types
where FDG PET/CT imaging has low diagnostic accuracy is currently being explored. Preliminary,
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mainly retrospective studies are encouraging, with evidence of improved diagnostic sensitivity and
specificity in CRCC, glioma, and HCC, leading to a change in patient management in several patients.
The results published thus far warrant confirmation by larger prospective studies additionally assessing
the longitudinal impact on patient outcomes.
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